L Perey
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.
Jan 1, 2007Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Jan 1, 2007Ann Oncol 2007; 18:64-9
Perey L, Goldhirsch A, Köberle Dieter, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann Beat
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Bernhard J, Goldhirsch A, Price K, Fey M, Thürlimann B, Veronesi A, Crivellari D, Rudenstam C, Snyder R, Collins J, Perey L, Forbes J, Murray E, Castiglione-Gertsch M, Gelber R, Coates A, Zahrieh D, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. BJC 2004; 91:1893-901.
Nov 29, 2004Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Nov 29, 2004BJC 2004; 91:1893-901
Bernhard J, Goldhirsch A, Price K N, Fey M F, Thürlimann Beat, Veronesi A, Crivellari D, Rudenstam C-M, Snyder R, Collins J, Perey L, Forbes J F, Murray E, Castiglione-Gertsch M, Gelber R D, Coates A S, Zahrieh D, Hürny C
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Sabbioni M, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Castiglione M, Bernhard J, Bacchi M, Siegrist H, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast cancer research and treatment 2000; 59:279-87.
Feb 1, 2000Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Feb 1, 2000Breast cancer research and treatment 2000; 59:279-87
Sabbioni M E, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann Beat, Castiglione M, Bernhard J, Bacchi M, Siegrist H P, Hürny C
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Sabbioni M, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann B, Bernhard J, Bacchi M, Siegrist H, Hürny C, Castiglione M, Senn H. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53.
May 1, 1999Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
May 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53
Sabbioni M E, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann Beat, Bernhard J, Bacchi M, Siegrist H P, Hürny C, Castiglione M, Senn H J
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A. Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. British journal of cancer 1998; 77:985-91.
Mar 1, 1998Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Mar 1, 1998British journal of cancer 1998; 77:985-91
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann Beat, Real O, Perey L, Bonnefoi H, Coates A